Abstract
The pathology of Alzheimer’s disease (AD) is characterized by the extracellular and intracellular accumulation of amyloid-β (Aβ) fibrillar plaques formed by the Aβ1-42 peptide, neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau, extensive neuritic and synaptic degradation, and neuron loss. One of the priorities for the treatment of AD is both the early detection and accurate chart progression of the accumulation of Aβ plaques in human brains. Molecular imaging tools can provide an in vivo visualization of Aβ plaques. Specific identification of amyloid plaques would allow a more accurate prognosis and ensure more effective clinical trials of anti-amyloid agents at earlier disease stage. The emphasis of this review is on the development of Aβ peptide radiopharmaceuticals or the ones combined with nanocarrierbased such as Molecular Trojan horses or nanoparticles for applications in in vivo amyloid imaging in AD.
Keywords: Alzheimer’s diagnosis, amyloid plaque imaging, amyloid radiopharmaceuticals, blood-brain barrier.
Current Radiopharmaceuticals
Title:Radiolabeled Peptides for Alzheimer’s Diagnostic Imaging: Mini Review
Volume: 6 Issue: 4
Author(s): Brianda Barrios-Lopez, Mari Raki and Kim Bergstrom
Affiliation:
Keywords: Alzheimer’s diagnosis, amyloid plaque imaging, amyloid radiopharmaceuticals, blood-brain barrier.
Abstract: The pathology of Alzheimer’s disease (AD) is characterized by the extracellular and intracellular accumulation of amyloid-β (Aβ) fibrillar plaques formed by the Aβ1-42 peptide, neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau, extensive neuritic and synaptic degradation, and neuron loss. One of the priorities for the treatment of AD is both the early detection and accurate chart progression of the accumulation of Aβ plaques in human brains. Molecular imaging tools can provide an in vivo visualization of Aβ plaques. Specific identification of amyloid plaques would allow a more accurate prognosis and ensure more effective clinical trials of anti-amyloid agents at earlier disease stage. The emphasis of this review is on the development of Aβ peptide radiopharmaceuticals or the ones combined with nanocarrierbased such as Molecular Trojan horses or nanoparticles for applications in in vivo amyloid imaging in AD.
Export Options
About this article
Cite this article as:
Barrios-Lopez Brianda, Raki Mari and Bergstrom Kim, Radiolabeled Peptides for Alzheimer’s Diagnostic Imaging: Mini Review, Current Radiopharmaceuticals 2013; 6 (4) . https://dx.doi.org/10.2174/1874471006666131126222835
DOI https://dx.doi.org/10.2174/1874471006666131126222835 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Current Neuropharmacology Polyphenols: Well Beyond The Antioxidant Capacity: Gallic Acid and Related Compounds as Neuroprotective Agents: You are What You Eat!
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Genetics of Parkinson's Disease and Other Diseases of the Extrapyramidal System)
Current Genomics Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry Heat Shock Proteins And Neuroprotection
Recent Patents on DNA & Gene Sequences Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer’s Disease
Current Pharmaceutical Design Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control?
Current Pharmaceutical Design Natural Products Triggering Biological Targets- A Review of the Anti-Inflammatory Phytochemicals Targeting the Arachidonic Acid Pathway in Allergy Asthma and Rheumatoid Arthritis
Current Drug Targets An Overview on Natural Cholinesterase Inhibitors - A Multi-Targeted Drug Class - and Their Mass Production
Mini-Reviews in Medicinal Chemistry Haptoglobin Phenotype Correlates with the Extent of Cerebral Deep White Matter Lesions in Hypertensive Patients
Current Neurovascular Research Fetzima (levomilnacipran), a Drug for Major Depressive Disorder as a Dual Inhibitor for Human Serotonin Transporters and Beta-Site Amyloid Precursor Protein Cleaving Enzyme-1
CNS & Neurological Disorders - Drug Targets The Role of Statins in Oxidative Stress and Cardiovascular Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Nutraceuticals, Nutritional Therapy, Phytonutrients, and Phytotherapy for Improvement of Human Health: A Perspective on Plant Biotechnology Application
Recent Patents on Biotechnology Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics Body Mass Index in Midlife and Risk of Alzheimer Disease and Vascular Dementia
Current Alzheimer Research Population Studies of Association Between Lithium and Risk of Neurodegenerative Disorders
Current Alzheimer Research Preface: Highlights of Recent Progress in Alzheimers Disease Research [ Hot Topics in Alzheimers Disease Research (Guest Editor: Debomoy K. Lahiri)]
Current Drug Targets BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry Change in Body Mass Index Before and After Alzheimer’s Disease Onset
Current Alzheimer Research